# 1. Financial Performance ## A. Key Figures * **Total Revenue:** **₹1,179 Cr** Q4 (+12% YoY) · **₹4,388 Cr** FY26 (+5% YoY) * **PAT:** **₹86 Cr** Q4 (+17% YoY, +84% QoQ) · **₹278 Cr** FY26 (+11% YoY) * **EPS (Basic):** **₹5.5** Q4 (+17% YoY) · **₹18** FY26 (+11% YoY) * **Net Debt/EBITDA:** **0.99x** (vs 1.2x+ historically) ## B. Revenue Growth * **Multi-Year Peak Performance:** Achieved highest quarterly revenue in 14 quarters, driven by robust **10% volume growth** and effective navigation of Middle East supply chain disruptions. * **Sequential Momentum:** Top-line growth showed significant acceleration in the final quarter, recovering from a three-year low of **₹966 Cr** in Q3FY24 to the current record high. * **Segment Contribution:** Growth was bolstered by a higher share of value-added CDMO products and improved contributions from the Fine Chemicals vertical. ## C. Margins & Profitability * **Operational Leverage:** Quarterly EBITDA growth significantly outpaced revenue growth on a sequential basis, reflecting improved scale and successful price pass-throughs. * **Segment Margin Expansion:** Specialty margins reached **27%** due to favorable mix, while Nutrition margins recovered to **14%** (from 11% QoQ) driven by the Cosmetics and Food segments. * **One-off Impacts:** Bottom-line results included a **₹13 Cr** impact from Indian labour code amendments and exceptional items, yet still delivered a record profit run-rate. * **Shareholder Returns:** Total dividend payout for FY26 reached **₹5 per share**, representing a 500% payout on face value. ## D. Cost Structure * **Input & Operational Costs:** Total expenses rose in tandem with revenue, primarily driven by a **24%** spike in raw material consumption and a **38%** increase in stock-in-trade purchases. * **Efficiency Gains:** Finance costs declined by double digits YoY, partially offsetting a **23%** rise in depreciation following recent capacity expansions. * **Energy Trends:** While quarterly power and fuel costs saw a marginal uptick, full-year energy expenses decreased by **10%**, aiding annual margin protection. ## E. Balance Sheet & Cash Flow * **Deleveraging Profile:** Net debt fell by double digits YoY to **₹587 Cr**, supported by a near doubling of cash reserves to **₹190 Cr** over the last 12 months. * **Working Capital Efficiency:** Cash conversion cycle improved significantly with Net Working Capital reduced to **59 days**, providing liquidity for the next growth phase. * **Currency Headwinds:** The closing USD/INR exchange rate shifted to **₹94.84**, marking a notable depreciation from **₹85.5** a year prior, impacting procurement and realization dynamics. --- # 2. Operating Segments ## A. Key Figures * **Specialty Chemicals:** **₹516 Cr** Q4 Rev (+6% YoY) · **₹1,937 Cr** FY26 Rev (+7%) · **₹139 Cr** Q4 EBITDA (+8% YoY) · **27%** Q4 Margin * Nutrition & Health: ₹230 Cr Q4 Rev (+21% YoY) · ₹790 Cr FY26 Rev (+6%) · ₹32 Cr Q4 EBITDA (+9% YoY) · 14% Q4 Margin * **Chemical Intermediates:** **₹433 Cr** Q4 Rev (+15% YoY) · **₹1,662 Cr** FY26 Rev (+3%) · **₹22 Cr** Q4 EBITDA (+111% YoY) · **5%** Q4 Margin ## B. Specialty Chemicals * **CDMO & Agro Tailwinds:** Robust segment performance was anchored by the commencement of a **large Agro contract** and a higher mix of value-added CDMO products. * **Global Leadership & Expansion:** Maintained top global positions in Pyridine and Picolines while successfully shipping innovator orders; strategy focuses on scaling **Oilfield and Semiconductor** chemicals. * **Strategic Recovery:** Segment EBITDA contribution showed a recovery trend to **11%** by year-end, following a significant historical decline from FY23 peaks. ## C. Nutrition & Health * **Volume-Led Growth:** Strong double-digit volume expansion in Vitamin B3 (Niacinamide) reached an **eight-quarter high** in the animal nutrition sector. * **Premiumization Strategy:** Margins benefited from a shift toward higher-value end-uses in **Cosmetics and Food** segments, offsetting pricing softness in certain feed categories. * **Infrastructure Investment:** Growth outlook is supported by a new **PC grade plant** for cosmetics and the launch of human nutrition premixes. ## D. Chemical Intermediates * **Operational Resilience:** Significant quarterly EBITDA growth was driven by effective cost pass-through and improved realizations in **Acetic Anhydride and Ethyl Acetate**. * **Market Share Gains:** Maintained a dominant **75%+ domestic share** in key intermediates and expanded footprint in the European merchant market despite Middle East supply disruptions. * **Full-Year Headwinds:** Despite a strong Q4 recovery, full-year EBITDA saw a sharp double-digit decline, reflecting a challenging pricing environment earlier in the fiscal year. ## E. Segment Mix * **High-Margin Pivot:** The portfolio has successfully shifted toward Specialty Chemicals and Nutrition, which now collectively represent **over 85%** of total EBITDA. * **Revenue Composition:** Specialty Chemicals remains the largest top-line contributor at **44%**, followed by Intermediates at **38%** and Nutrition at **18%**. * **Diversified End-Markets:** The business now services a broad spectrum including Pharma, Agro, Consumer, and the nascent but high-growth **Semiconductor** sector. --- # 3. Product & Market Performance ## A. Key Figures * **CDMO Pipeline Potential:** **₹3,400 Cr** total (100+ opportunities) · **₹1,500 Cr** confirmed (20+ molecules) * **Advanced Stage Pipeline:** **₹1,100 Cr** peak revenue potential (10+ molecules) * **Geographic Revenue Mix:** **56%** India · **24%** Europe · **8%** North America · **12%** Rest of World ## B. Volume & Pricing * **Broad-Based Volume Recovery:** Robust growth achieved across all segments, highlighted by Vitamin B3 (Niacinamide) reaching an **eight-quarter volume high** and double-digit growth in Ethyl Acetate. * **Pricing Dynamics & Cost Pass-Through:** Successfully implemented price hikes in Agrochem and Acetyls to offset higher crude-linked input costs; however, pricing in Fine Chemicals remains pressured by **Chinese competition**. * **Market Share Gains:** Strengthened footprint in Europe for Acetyls (Acetic Anhydride) while leveraging resilient domestic pharmaceutical demand to stabilize volumes. ## C. CDMO & Pipeline * **Strategic Pivot to Specialty:** Aggressive transformation toward high-value CDMO services for Agro and Pharma, evidenced by the commencement of dispatches for a **major global Agro order** in March 2024. * **R&D & Infrastructure Expansion:** Tripled the Pharma pipeline over two years; currently scaling a team of **150+ R&D personnel** and developing a dedicated **Semiconductor R&D lab** in Greater Noida. * **Launch Visibility:** Pipeline of **50+ products** under management, with the highest density of new product launches projected for **FY27**. ## D. Geography & Customer Metrics * **International Scaling:** North America and Europe now constitute nearly one-third of revenue, with specialized portfolios (CC/CBT) gaining significant traction in Western markets. * **Key Account Momentum:** The KAM program has successfully converted **20+ wins** from a high-engagement funnel of the top 40 customers, targeting a multi-billion rupee peak potential. * **Diversified End-Use:** Revenue remains well-balanced between defensive sectors (Pharma/Nutrition at **53%**) and cyclical industrial/consumer segments. --- # 4. Manufacturing & Technology ## A. Key Figures * **Quarterly Capex Outflow:** **₹69 Cr** Bharuch/Gajraula projects * **Lean Savings:** **₹120+ Cr** delivered in FY26 · **₹100+ Cr/year** achieved * **Working Capital to Revenue:** **16%** Current period (vs. 18% Q4'FY25) * **R&D & Workforce:** **150** Scientists · **3** R&D Centres · **2,300+** Employees * **Infrastructure:** **5** Manufacturing facilities · **50+** Plants ## B. Capacity & Capex * **CDMO Roadmap Acceleration:** Ongoing construction of the Gajraula Multi-Purpose Plant (MPP) and commissioning of the Bharuch facility underpin long-term growth strategy. * **Rapid Project Execution:** Successfully completed the Agro CDMO facility construction and commissioning in a record **14-month** timeframe. * **Strategic Investment Scale:** Deployed **₹2,000 Cr** toward new plant construction to enhance infrastructure and operational efficiency. ## C. R&D & Innovation * **Advanced Chemistry Portfolio:** Integrated solutions powered by a diverse base of **35+ chemistries**, focusing on high-entry-barrier technical investments. * **Specialized Technology Focus:** Capitalizing on Flow, Cryogenic, and Semicon purification technologies via a newly established Dedicated Technology Cell. ## D. Digital Transformation * **AI-Driven Efficiency:** Launched the "SuperNova" program featuring **50+ Digital and AI initiatives**, including GenAI tools to accelerate R&D and streamline corporate functions. * **Global Recognition:** Inducted into the World Economic Forum’s **Global Lighthouse Network** in 2024, recognizing the successful deployment of 4IR technologies and "Smart Plants." ## E. Operational Excellence * **Regulatory & Quality Benchmarks:** Achieved a USFDA plant audit with **zero observations** and delivered complex multi-step chemistry molecules using a "First-time right" approach. * **Sustainability Leadership:** Ranked in the **97th percentile** of the S&P Global CSA; operations now utilize **35% green power** alongside top-tier ESG certifications. * **Supply Chain Resilience:** Maintained operational continuity through agile management despite geopolitical disruptions in the Middle East. --- # 5. Strategic Initiatives ## A. Key Figures * **Strategic Timeline:** **2 Years** since Pinnacle journey launch * **Project Investment:** **$300M** Agro-Innovator project commissioned * **End-Market Verticals:** **6** focused segments (Pharma, Agro, Industrial, Personal Care, Nutrition, Semicon) ## B. Pinnacle Journey & Portfolio Optimization * **Strategic Transformation:** The "Pinnacle" initiative has matured, delivering a leaner cost structure, a strengthened balance sheet, and an improved portfolio mix across three core pillars. * **Operational Enablers:** Execution is underpinned by a "customer-first" model, digital transformation, and deep R&D integration to drive long-term growth. * **Agro CDMO Milestone:** Achieved the first commercial dispatch from the new Agro CDMO facility, marking a critical step in high-value manufacturing scaling. ## C. M&A & Market Expansion * **Human Nutrition Acceleration:** Completed the acquisition of **Remidex Pharma**, facilitating immediate entry into the customized Vitamin and Mineral Premix market. * **Tier-1 Customer Traction:** The Remidex integration has already secured engagement with major domestic tier-1 customers, stabilizing pricing and volume growth. * **Future-Tech Investments:** Board approved CAPEX for a **Semiconductor R&D and Pilot lab** in Greater Noida, signaling a strategic pivot toward high-growth electronics chemicals. ## D. Organizational & Supply Chain Evolution * **Verticalized Structure:** Transitioned to a specialized business model with dedicated leadership for six end-verticals to enhance customer centricity and technical focus. * **Supply Chain Resilience:** Implemented predictive analytics for raw material procurement and logistics tracking; successfully navigated Middle East logistics crises with zero production downtime. * **Talent Infusion:** Significant strengthening of the leadership bench across Supply Chain Management (SCM), Manufacturing HR, and Design & Tech functions. --- # 6. Risks & External Factors ## A. Supply Chain & Geopolitical Dynamics * **Operational Resilience Amid Conflict:** Maintained uninterrupted supply chains despite Middle East disruptions through diversified sourcing, successfully avoiding force majeure events. * **Market Share Gains:** Capitalized on European plant closures and force majeure events to capture market shifts and improve segment momentum. * **Geopolitical Pricing Tailwinds:** Middle East-related disruptions and crude inflation are driving price escalations across segments. ## B. Chinese Competitive Landscape * **Anti-Dumping Tailwinds:** Choline volumes saw significant YoY and QoQ expansion as Chinese import pressure eased, specifically gaining traction in the EU following new **anti-dumping duties**. * **Pricing Suppression:** Persistent oversupply and competitive intensity from China continue to pressure margins in Agrochemicals and P&P, despite a gradual recovery in volumes. * **Nascent Pricing Recovery:** While P&P pricing remained muted for the majority of the period, a positive pricing inflection was observed toward the end of the quarter. ## C. Raw Material & Realization Trends * **Cost Pass-Through Efficiency:** Revenue and EBITDA growth were bolstered by the successful pass-through of higher raw material costs to customers. * **Input Cost Volatility:** Chemical Intermediates performance benefited from a sharp spike in **Acetic Acid prices** and crude-linked inflation. ## D. ESG & Compliance * **Sustainability Leadership:** Secured high global rankings in the **Dow Jones Sustainability Index** and **Ecovadis**, supported by Responsible Care certification. --- # 7. Guidance & Outlook ## A. Key Figures * **FY26 Revenue Forecast:** **₹4,388 Cr** Consolidated (+6%) * **FY26 EBITDA Forecast:** **₹607 Cr** Consolidated (+33%) * **FY26 EBITDA Margin:** **~14%** Consolidated (+300 bps vs FY24) ## B. FY27 Growth Targets & Revenue Potential * **Strategic Growth Drivers:** Future expansion is anchored by the **Specialty Chemicals and Nutrition** verticals, complemented by a cyclical recovery in the **Acetyls** segment. * **Sequential Momentum:** Management anticipates a positive inflection point starting in **Q1FY27**, with projected quarter-on-quarter improvements in both top-line and operating profit. * **Profitability Step-up:** Forecasted performance indicates significant margin expansion compared to FY24 levels, driven by an improved business mix and volume recovery.